Sage Therapeutics (NASDAQ:SAGE) Shares Up 2.7%

Sage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) shot up 2.7% during mid-day trading on Tuesday . The company traded as high as $11.50 and last traded at $11.48. 397,868 shares were traded during mid-day trading, a decline of 62% from the average session volume of 1,044,326 shares. The stock had previously closed at $11.18.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on SAGE. Mizuho lowered their price objective on shares of Sage Therapeutics from $20.00 to $18.00 and set a "neutral" rating on the stock in a report on Friday, April 26th. Needham & Company LLC reissued a "hold" rating on shares of Sage Therapeutics in a research note on Thursday, April 25th. StockNews.com raised shares of Sage Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, April 27th. HC Wainwright decreased their target price on shares of Sage Therapeutics from $28.00 to $25.00 and set a "neutral" rating for the company in a research note on Friday, April 26th. Finally, TD Cowen decreased their target price on shares of Sage Therapeutics from $30.00 to $16.00 and set a "buy" rating for the company in a research note on Thursday, April 18th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $37.67.

Sage Therapeutics Stock Up 7.8 %

The firm has a market cap of $725.17 million, a price-to-earnings ratio of -1.43 and a beta of 0.91. The stock has a 50 day moving average of $15.39 and a 200 day moving average of $19.87.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.80) EPS for the quarter, missing analysts' consensus estimates of ($1.63) by ($0.17). The company had revenue of $7.90 million during the quarter, compared to analyst estimates of $5.26 million. Sage Therapeutics had a negative net margin of 552.52% and a negative return on equity of 56.81%. The firm's revenue for the quarter was up 139.4% compared to the same quarter last year. During the same period last year, the firm earned ($2.46) EPS. As a group, analysts predict that Sage Therapeutics, Inc. will post -6.53 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC bought a new position in shares of Sage Therapeutics in the first quarter worth about $187,000. Baker BROS. Advisors LP bought a new position in shares of Sage Therapeutics in the first quarter worth about $7,631,000. Bellevue Group AG lifted its holdings in shares of Sage Therapeutics by 27.1% in the first quarter. Bellevue Group AG now owns 4,465,544 shares of the biopharmaceutical company's stock worth $83,684,000 after acquiring an additional 952,193 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Sage Therapeutics by 69.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 811,934 shares of the biopharmaceutical company's stock worth $15,217,000 after acquiring an additional 333,805 shares during the last quarter. Finally, Lazard Asset Management LLC bought a new position in shares of Sage Therapeutics in the first quarter worth about $127,000. Institutional investors and hedge funds own 99.22% of the company's stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.